Hayden is an assistant editor for The American Journal of Managed Care® (AJMC®) and joined AJMC® in 2021, where she produces written and video content covering multiple disease states.
She has a BA in journalism & media studies from Rutgers University. You can connect with Hayden on LinkedIn.
Genetic RA Associated With Inflammatory Bowel Disease, but Not Other Way Around
March 16th 2022The genetically-predicted risk of rheumatoid arthritis (RA) was positively associated with an increased risk of inflammatory bowel disease (IBD) and potentially with its main subtypes, ulcerative colitis and Crohn disease.
Read More
Mount Sinai Researchers Discuss Milestones in Understanding Genetic Variants
March 14th 2022Ron Do, PhD, associate professor, Charles Bronfman Institute for Personalized Medicine at Mount Sinai, and Iain Forrest, MD-PhD candidate in Dr Do’s lab, discuss their hopes for their findings and how genetic data are being used in health care.
Read More
Telemonitoring Just as Beneficial as In-Person Monitoring for Patients With RA Initiating DMARDs
March 12th 2022Using telemedicine to monitor patients with rheumatoid arthritis (RA) initiating disease-modifying antirheumatic drugs (DMARDs) was highly cost-effective and resulted in similar health outcomes compared with in-person monitoring.
Read More
Mount Sinai Researchers Explain Implications of Genetic Testing for Providers
March 12th 2022Ron Do, PhD, associate professor, Charles Bronfman Institute for Personalized Medicine at Mount Sinai, and Iain Forrest, MD-PhD candidate in Dr Do’s lab, explain their study's implications for providers and how age plays a role in genetic variant penetrance.
Read More
RA, But Not Related Autoimmunity, Associated With Increased CV Risk
March 5th 2022According to the study, rheumatoid arthritis (RA)-associated autoimmunity was not linked to increased cardiovascular (CV) event risk, suggesting systemic inflammation is likely required for precipitating CV events.
Read More
Mount Sinai Researchers Explain Biobanks Used in Clinical Variants Study
March 4th 2022Ron Do, PhD, associate professor, Charles Bronfman Institute for Personalized Medicine at the Icahn School of Medicine at Mount Sinai, and Iain Forrest, MD-PhD candidate in Dr Do’s lab, explain the differences between the biobanks used in their study on population-based penetrance of clinical variants.
Read More
HIV, HCV Testing Availability Stagnates Despite Growing Number of Substance Use Treatment Facilities
March 3rd 2022Although thousands of new substance use disorder treatment facilities that offer medication for opioid use disorder were opened between 2017 and 2020, the proportion of facilities that also offered HIV and hepatitis C virus (HCV) testing hardly changed.
Read More
NFID Board Members on How RSV Affects Different Age Groups
February 27th 2022William Schaffner, MD, medical director at the National Foundation for Infectious Diseases (NFID), and Patsy Stinchfield, RN, MS, CPNP, president-elect of NFID, discuss how respiratory syncytial virus (RSV) affects different age groups.
Read More
Mount Sinai Researchers Discuss Findings on Risk of Pathogenic, Loss-of-Function Clinical Variants
February 26th 2022Ron Do, PhD, associate professor, Charles Bronfman Institute for Personalized Medicine at the Icahn School of Medicine at Mount Sinai, and Iain Forrest, MD-PhD candidate in Dr Do’s lab, discuss the results of their recent study measuring population-based penetrance of pathogenic and loss-of-function clinical variants.
Read More
Dr Ted Mikuls Explains Gout Study's Regional Data, Findings on Urate Control
February 26th 2022Ted Mikuls, MD, MSPH, Stokes-Shackleford Professor of Rheumatology, vice chair for research, internal medicine, at the University of Nebraska, discusses findings on urate-lowering therapy and the lack of regional data on gout-related lower-extremity amputation.
Read More
Drop in HIV PrEP Prescriptions, New Users Observed During COVID-19 Pandemic
February 25th 2022A data analysis found a 22% reduction in HIV pre-exposure prophylaxis (PrEP) prescriptions and a 25% reduction in new PrEP users in the United States after COVID-19 was declared a national emergency.
Read More
Dr Sunil Verma Discusses Adding Durvalumab to Cholangiocarcioma Chemotherapy Combination
February 25th 2022Sunil Verma, MD, senior vice president and global head of oncology, medical, at AstraZeneca, discusses the addition of durvalumab to a chemotherapy regimen of gemcitabine and cisplatin for biliary duct cancer.
Read More
Transesophageal Echocardiography Not Linked With Respiratory Failure, Study Finds
February 23rd 2022The 28-day cumulative risk of respiratory failure after transesophageal echocardiography (TEE) was similar to the risk measured in those go did not undergo TEE, a procedure performed after a transient ischemic attack or stroke.
Read More
Analysis Identifies Predictors of Disease Flare for Patients With RA in Remission
February 23rd 2022Defined cut-off scores for patient function and MRI-detected bone erosion may potentially help clinicians and patients with rheumatoid arthritis (RA) in remission decide when to stop treatment.
Read More
Dr Funmi Olopade Describes Advancements in BRCA Gene Testing
February 20th 2022Funmi Olopade, MD, FACP, professor of medicine and human genetics and founding director of the Center for Clinical Cancer Genetics and Global Health at the University of Chicago Medical Center, explains advancements in BRCA testing and how genetic testing has become standard of care.
Read More
Dr Ted Mikuls Discusses Gout Interventions to Prevent Amputation
February 19th 2022Ted Mikuls, MD, MSPH, Stokes-Shackleford professor of rheumatology, vice chair for research, internal medicine at the University of Nebraska, discusses interventions and treatments that could prevent lower extremity amputation for people with gout.
Read More
Mount Sinai Researchers on Importance of Understanding Genetic Variants and Disease Risk
February 19th 2022Ron Do, PhD, associate professor of the Charles Bronfman Institute for Personalized Medicine at the Icahn School of Medicine at Mount Sinai, and Iain Forrest, MD-PhD candidate in Dr Do’s lab, explain the importance of their recent study measuring population-based penetrance of pathogenic and loss-of-function clinical variants.
Read More
Dr Dennis Scanlon Discusses End-of-Year Letter on Health Care Innovation
February 18th 2022Dennis P. Scanlon, PhD, professor of health policy and administration at Pennsylvania State University and editor-in-chief of The American Journal of Accountable Care, discusses his 2021 end-of-year letter calling on health system leaders to learn and innovate in real time.
Read More